300363 Porton Pharma Solutions
- 15.93
- +0.24+1.53%
Porton Pharma Solutions News
Boteng Co., Ltd. (300363.SZ): Can provide CDMO services for different types of drugs and therapies such as small molecule drugs, large molecule drugs, and gene cell therapy
Gelonghui, May 10 | Boteng Co., Ltd. (300363.SZ) said on the investor interactive platform that the company is a pharmaceutical R&D and production outsourcing organization (CDMO) that provides full-category, end-to-end services for pharmaceutical companies, biotechnology companies, scientific research institutions, etc. on a global scale, and can provide CDMO services for different types of drugs and therapies such as small molecule drugs, large molecule drugs, and gene cell therapy. The company continues to invest in R&D resources to establish an interdisciplinary innovative technology platform covering drug crystallization, biocatalysis, fluid chemistry, micronized powders, highly active drugs, preparation chromatography, fluorine chemistry, photochemistry,
Zhitong A Share Sale Restriction and Release List | May 10
According to the Zhitong Finance App, the ban on restricted shares of 13 listed companies was lifted on May 10, with a total market value of about 28.01 billion yuan. Today's specific restricted shares are as follows: Stock abbreviation, stock code, restricted share type, number of unbanned shares: Xiamen Cinda 000701 shares, original shareholders placed 120 million, Cangzhou Dahua 600230, share incentives, 2.142,400, share incentives, restricted circulation 20375 million, Jinfu Technology 300128 additional A-shares, corporate placement and listing of 205 million yuan Dazhong Mining 001203 shares before issuance
Boteng Co., Ltd. (300363) Company Information Update Report: Regular business growth is steady, profit side is under phased pressure
Regular business growth is steady. Affected by multiple factors, the profit side is under phased pressure. In 2023, the company achieved revenue of 3,667 billion yuan, a year-on-year decrease of 47.87%. Excluding major orders, revenue increased by about 10% year on year; net profit to mother
Boteng Co., Ltd. (300363): Continuing to consolidate the small molecule pipeline and expect profit margin restoration
2023&2024Q1 results are lower than our expected 2023 results: revenue of 3.667 billion yuan, revenue up about 10% year on year after excluding the impact of major orders; net profit to mother 267 million yuan, -86.6 million yuan year on year
Boteng Co., Ltd. (300363): Insufficient capacity utilization, short-term performance under pressure, profitability is expected to improve quarterly
In 2023, the company achieved operating income of 3.667 billion yuan (-47.87%), and revenue after excluding major orders increased by about 10% year-on-year; net profit to mother was 267 million yuan (-86.69%), after deducting net income from mother
Boteng Co., Ltd. (300363.SZ) announced first-quarter results, with a net loss of 94.8708 million yuan, a year-on-year profit to loss
Boteng Co., Ltd. (300363.SZ) released its report for the first quarter of 2024, and the company achieved revenue during the reporting period...
Express News | Boteng Antibody and ADC GMP pilot production lines completed and put into operation
Boteng Co., Ltd. (300363.SZ): A total cost of 19.394,500 yuan to buy back 0.12% of the shares
Gelonghui Co., Ltd. (300363.SZ) announced that as of February 29, 2024, the company had repurchased 660,000 shares of the company's shares through a special stock repurchase securities account, accounting for 0.12% of the company's current total share capital. The highest transaction price was 32.00 yuan/share, the lowest transaction price was 27.01 yuan/share, and the total transaction amount was 19.3945 million yuan.
Boteng Co., Ltd. (300363.SZ): 2023 Employee Stock Ownership Plan to Complete Stock Purchase
Gelonghui, Feb. 27丨Boteng Shares (300363.SZ) announced that as of February 27, 2024, the 2023 employee stock ownership plan had purchased a total of 2,099,892 shares of the company's shares through centralized bidding transactions in the secondary market, accounting for 0.38% of the company's total share capital. The total transaction amount was 39,012,787.84 yuan, and the average transaction price was 18.58 yuan/share.
Boteng Co., Ltd. (300363.SZ) plans to invest no more than 50 million yuan in the Xingze Phase IV Fund to lay out innovative life science enterprises
Boteng Co., Ltd. (300363.SZ) announced that the company plans to use its own funds to pledge an investment of no more than 50 million yuan to participate...
Boteng Co., Ltd. (300363.SZ): Intended to participate in the subscription of investment fund shares
Gelonghui, Feb. 23 | Boteng Co., Ltd. (300363.SZ) announced that the company plans to invest no more than 50 million yuan with its own funds to participate in the Suzhou Xingze Xingyong Emerging Medical Industry Investment Fund Management Partnership managed by Shanghai Xingze Investment Management Co., Ltd., as a limited partner, with a fund size of 15-20 billion yuan. Mainly investing in innovative biomedicine, biotherapy and bioengineering products, including and not limited to macromolecular biopharmaceuticals, small-molecule targeted drugs, cell therapy, gene therapy, etc.; innovative medical devices, including but not limited to innovative consumables and devices; and research
Boteng Co., Ltd. (300363.SZ): Jiangxi Boteng has been re-certified as a high-tech enterprise
Gelonghui Co., Ltd. (300363.SZ) announced that Jiangxi Boteng Pharmaceutical Co., Ltd. (“Jiangxi Boteng”), a wholly-owned subsidiary of the company, recently received the “High-tech Enterprise Certificate” jointly issued by the Jiangxi Provincial Department of Science and Technology, the Jiangxi Provincial Department of Finance, and the Jiangxi Provincial Taxation Bureau of the State Administration of Taxation.
Boteng Co., Ltd. (300363): After delivery of large orders, focus on improving capacity utilization
The company announced a year-on-year decrease of 83-88% in net profit in 2023. The company issued a performance forecast: in 2023, revenue of 35.2-2.87 billion yuan, a year-on-year decrease of 45-50%, net profit of 24—340 million yuan, same
Boteng Co., Ltd. (300363.SZ): 2023 net profit pre-reduced by 83% — 88%
On January 26, Ge Longhui Co., Ltd. (300363.SZ) announced its 2023 annual performance forecast. Net profit profit attributable to shareholders of listed companies during the reporting period was 240 million yuan to 341 million yuan, down 83% — 88% from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 285.22 million yuan - 386.22 million yuan, down 80% — 86% from the same period last year; operating income of 3517.4 million yuan to 386,9.14 million yuan, down 45% from the same period last year. In 2023, the company expects to achieve operating income
Minsheng Securities: The policy favors the transfer of overseas drugs to domestic production, optimistic about domestic CDMO leaders
The transfer of drugs produced overseas to domestic production ushered in favorable policies, and China's high-quality production capacity is expected to accelerate its entry into the supply chain of overseas pharmaceutical companies.
Boteng Biotech warmly congratulates Enkai Pharmaceutical's NK010 injection for obtaining clinical trial approval for a new drug from the US FDA
SUZHOU, January 23, 2024/PRNewswire/ -- On January 17, 2024, a non-genetically-modified natural killer cell injection (project code NK010) independently developed by Shanghai Enkai Cell Technology Co., Ltd. (“NK010”) obtained approval from the US Food and Drug Administration (FDA) for phase I clinical trials (IND). Currently, this product is the first non-genetically modified allogenetically modified peripheral blood NK cell drug approved by the FDA in China. Boteng Biotech warmly congratulates them on this. NK010 has optimized receptor spectrum, diverse targets, high purity, and universality
Boteng shares (300363.SZ): a total cost of 19.394,500 yuan to buy back 660,000 shares
Gelonghui Co., Ltd. (300363.SZ) announced that as of December 31, 2023, the company had repurchased 660,000 shares of the company's shares through a special stock repurchase securities account, accounting for 0.12% of the company's current total share capital. The highest transaction price was 32.00 yuan/share, the minimum transaction price was 27.01 yuan/share, and the total transaction amount was 19.3945 million yuan (excluding handling fees).
Boteng Co., Ltd. (300363.SZ): The terminal drug of the service involves a wide range of indications
Glonghui, December 13|Some investors asked Boteng Co., Ltd. (300363.SZ) on the investor interactive platform, “Does the company's service outsourcing include cardiovascular, cerebrovascular, Alzheimer's disease, diabetes, and high blood pressure?” The company replied that the terminal drugs served by the company cover a wide range of indications, and the above fields are covered in the company's history or current service projects.
Boteng Co., Ltd. (300363): Leading domestic CDMO expects new business to enter a harvest period
For the first time, investment highlights covered Boteng Shares (300363), which gave it an outperforming industry rating. The target price is 33.00 yuan, corresponding to 20.5/20.1 times 2023/2024 based on the P/E valuation method. The reason is as follows: Bo
Dealing with COVID-19 XBB variants: Five vaccines incorporated into emergency use catalytic domestic mRNA technology|Industry Watch
① Recently, five consecutive COVID-19 vaccines have been included in emergency use. Their common characteristic is that they are all designed for the XBB variant, reflecting the relevant departments' consideration of “updating” the COVID-19 vaccine bank in a timely manner. Virus experts also believe that now is a good time to get vaccinated; ② Due to the accumulation of technology in vaccine research and development, the “blue ocean” of mRNA vaccines is slowly rolling out, and domestic vaccine companies are expected to catch up with international advanced levels.
Analysis
Price Target
No Data
